Related Experiment Videos
Drug interaction: rifampicin and glibenclamide
V Surekha1, J V Peter, L Jeyaseelan
1Christian Medical College and Hospital, Vellore, Tamil Nadu, India.
The National Medical Journal of India
|January 1, 1997
Summary
Rifampicin significantly worsens blood sugar control in diabetic patients taking glibenclamide, necessitating dose adjustments. Blood glucose levels returned to normal after discontinuing rifampicin.
Area of Science:
- Pharmacology
- Endocrinology
- Drug Interactions
Background:
- Rifampicin is a potent inducer of hepatic microsomal enzymes.
- Rifampicin is known to interact with numerous medications.
- The interaction between rifampicin and glibenclamide requires investigation.
Purpose of the Study:
- To evaluate the interaction between rifampicin and glibenclamide.
- To determine the effect of rifampicin on blood glucose control in patients on glibenclamide therapy.
Main Methods:
- Twenty-nine diabetic patients on glibenclamide therapy were enrolled.
- Patients received either 450 mg or 600 mg of rifampicin daily for 10 days.
- Blood glucose levels were monitored before and after rifampicin administration.
Main Results:
- Rifampicin administration led to a significant worsening of fasting and post-prandial blood sugar (p < 0.001).
- Fifteen out of seventeen patients with initially controlled diabetes required glibenclamide dose modification due to uncontrolled blood sugar.
- Blood sugar normalized within six days after cessation of rifampicin.
Conclusions:
- Rifampicin and glibenclamide exhibit a clinically significant interaction.
- Dose adjustments of glibenclamide are crucial when co-administered with rifampicin to maintain euglycemia.
- This interaction highlights the importance of monitoring blood glucose in patients receiving both medications.